AGS, 2020 [19] | CDC, 2020 [25] | ECRI, 2020a [26] | ECRI, 2020b [20] | Geffen, 2020 | HPS, 2020 [23] | Lester, 2020 [24] | MOH, 2020 [27] | WHO, 2020 [21] | |
---|---|---|---|---|---|---|---|---|---|
Domain 1: Scope and purpose (12 points in total) | |||||||||
Item 1: Objectives | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
Item 2: Questions | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
Item 3: Population | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 2 |
Totals | 6 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 3 |
Domain 2: Stakeholder involvement (11 points in total) | |||||||||
Item 4: Group membership | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 |
Item 5: Target population preferences and views | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Item 6: Target users | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 |
Totals | 2 | 1 | 0 | 1 | 2 | 2 | 6 | 1 | 1 |
Domain 3: Rigour of development (35 points in total) | |||||||||
Item 7: Search methods | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Item 8: Evidence selection criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 9: Strengths and limitations of the evidence | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 10: Formulation of recommendations | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Item 11: Consideration of benefits and harms | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 12: Link between recommendations and evidence | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 13: External review | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 14: Updating procedure | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Totals | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
Domain 4: Clarity of presentation (8 points in total) | |||||||||
Item 15: Specific and unambiguous recommendations | 3 | 3 | 3 | 1 | 2 | 2 | 3 | 2 | 1 |
Item 16: Management options | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
Item 17: Identifiable key recommendations | 0 | 1 | 2 | 0 | 2 | 2 | 2 | 1 | 1 |
Totals | 3 | 4 | 7 | 2 | 5 | 5 | 6 | 4 | 3 |
Domain 5: Applicability (13 points in total) | |||||||||
Item 18: Facilitators and barriers to application | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 19: Implementation advice/tools | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
Item 20: Resource implications | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Item 21: Monitoring/auditing criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Totals | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
Domain 6: Editorial independence (6 points in total) | |||||||||
Item 22: Funding body | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 1 |
Item 23: Competing interests | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Totals | 2 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 1 |